Research Articles | Page 10 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Sep 2013 Ann Hematol myelodysplastic syndromes (MDS)
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function Apr 2014 Ann Hematol myelodysplastic syndromes (MDS)
Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia Aug 2017 Ann Hematol aplastic anemia
Asymptomatic cerebral bleeds in patients with aplastic anemia. Mar 2012 Ann Hematol aplastic anemia
Multiparameter FLAER-based flow cytometry for screening of paroxysmal nocturnal hemoglobinuria enhances detection rates in patients with aplastic anemia Dec 2014 Ann Hematol aplastic anemia
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. May 2013 Ann Hematol myelodysplastic syndromes (MDS)
Efficacy and safety of deferasirox in myelodysplastic syndromes Feb 2013 Ann Hematol myelodysplastic syndromes (MDS)
Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients Jul 2013 Ann Hematol myelodysplastic syndromes (MDS)
Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability. May 2013 Ann Hematol myelodysplastic syndromes (MDS)
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab Jan 2017 Ann Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Share with addtoany.com.